Would you like to help/fact check this? It frustrates me you can't find efficacy head-to-head in a simple chart. I have it as a table in a Word doc but can't import. I started with meds that favorably impact brain atrophy, although Tec has no data for that yet. I hope the text doesn't wrap and it's legible. Maybe a moderator would left align if that happens.
Relapse Rate Reduction annual
Tysabri 68%
Avonex/Rebif 32%, 33%
Fingolimod (Gilenya) 54%
BG-12 53%, 44%
Disability Progression Retardation
Tysabri 42%
Avonex/Rebif
Fingolimod (Gilenya) 30% (three month progression over two years)
BG-12 38%, 21%
New or Enlarging Lesions T2 Reduction
Tysabri 83%
Avonex/Rebif
Fingolimod (Gilenya) 74%
BG-12 85%, 71%
Side Effects (partial listing)
Tysabri Death (rare), liver
Avonex/Rebif Blood cell count, liver, depression/suicide, flu like symptoms, seizures
Fingolimod (Gilenya) Liver, abnormal heart function
BG-12 Flushing, upset stomach cancer?-animal trials
*Different data points indicate separate studies
Relapse Rate Reduction annual
Tysabri 68%
Avonex/Rebif 32%, 33%
Fingolimod (Gilenya) 54%
BG-12 53%, 44%
Disability Progression Retardation
Tysabri 42%
Avonex/Rebif
Fingolimod (Gilenya) 30% (three month progression over two years)
BG-12 38%, 21%
New or Enlarging Lesions T2 Reduction
Tysabri 83%
Avonex/Rebif
Fingolimod (Gilenya) 74%
BG-12 85%, 71%
Side Effects (partial listing)
Tysabri Death (rare), liver
Avonex/Rebif Blood cell count, liver, depression/suicide, flu like symptoms, seizures
Fingolimod (Gilenya) Liver, abnormal heart function
BG-12 Flushing, upset stomach cancer?-animal trials
*Different data points indicate separate studies